FindTrial
Sign In

Effects of octreotide LAR treatment on QOL, clinical symptoms and endocrinological data in patients with acromegaly or pituitary gigantism

Effects of octreotide LAR treatment on QOL, clinical symptoms and endocrinological data in patients with acromegaly or pituitary gigantism - Effects of octreotide LAR treatment on QOL in acromegalic patients

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000258
Enrollment
50
Registered
2005-10-05
Start date
2005-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acromegaly and pituitary gigantism

Interventions

Octreotide LAR 10mg-40mg

Sponsors

Kansai Study Groups for Hypothalamic and Pituitary Diseases
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) The age is 20 years old or more. 2) Patients diagnosed with acromegaly or pituitary gigantism according to the criteria by

Exclusion criteria

Exclusion criteria: 1) Patients who have previous history of hypersensitivity for elements of Octreotide. 2) Patients whose serum bilirubin or serum creatinine concentration exceeds three times of the upper level of normal ranges. 3) Patients whose AST(GOT) or ALT(GPT) concentration exceeds five times of the upper level of normal ranges.

Design outcomes

Primary

MeasureTime frame
1. QOL(SF-36) 2. Clinical symptom(headache, sweating, arthralgia, carpal-tunnel syndrome, and other clinical symptoms) 3. Serum GH 4. Serum IGF-1—

Secondary

MeasureTime frame
1. Complication(blood pressure, glucose tolerance status, dyslipidemia, and cardiovascular diseases 2. Adverse events—

Countries

Japan

Contacts

Public ContactSoji Kasayama

Osaka University Graduate School of Medicine Department of Medicine (Endaocrinology and Metabolism)(C-4)

kasayama@imed3.med.osaka-u.ac.jp06-6879-3831

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026